|1.||Furuya, Hitoshi: 3 articles (09/2006 - 07/2002)|
|2.||Inoue, Satoki: 3 articles (09/2006 - 07/2002)|
|3.||Sakamoto, Takanori: 2 articles (10/2002 - 07/2002)|
|4.||Kitaguchi, Katsuyasu: 2 articles (10/2002 - 07/2002)|
|5.||Kawaguchi, Masahiko: 2 articles (10/2002 - 07/2002)|
|6.||Schmidt, H: 2 articles (09/2000 - 09/2000)|
|7.||Tinelli, M: 2 articles (09/2000 - 09/2000)|
|8.||Schmidt, W: 2 articles (09/2000 - 09/2000)|
|9.||Martin, E: 2 articles (09/2000 - 09/2000)|
|10.||Gebhard, M M: 2 articles (09/2000 - 09/2000)|
07/22/1985 - "Animal and human studies suggest that amrinone can cause significant improvement in the systemic hemodynamics of patients with severe congestive heart failure (CHF), and do so without increasing myocardial oxygen consumption. "
07/01/1981 - "Amrinone, a new inotropic agent, has been shown to be beneficial in patients with congestive heart failure. "
11/01/1984 - "Failure of low doses of amrinone to produce sustained hemodynamic improvement in patients with severe chronic congestive heart failure."
03/01/1987 - "Thus, intravenous amrinone proved effective in patients with severe heart failure, with maximal effects being obtained in doses of 3 mg X min-1."
05/01/1984 - "It is concluded that amrinone is effective in the long-term treatment of chronic cardiac failure."
|2.||Pulmonary Hypertension (Ayerza Syndrome)
09/01/1986 - "The aim of this study was to investigate the haemodynamic effects of amrinone in patients with pulmonary hypertension and impaired right ventricular function. "
08/01/1996 - "Lungs were examined for immunohistochemical evidence of PDGF and bFGF, and hearts were examined for effects of pulmonary hypertension and amrinone. "
11/01/1993 - "Effect of amrinone during group B Streptococcus-induced pulmonary hypertension in piglets."
11/01/1993 - "Amrinone therapy for severe pulmonary hypertension and biventricular failure after complicated valvular heart surgery."
10/01/1993 - "The sole child with postoperative pulmonary hypertension had a beneficial decrease in pulmonary artery pressure, increase in cardiac index, and stable systemic blood pressure during amrinone use. "
|3.||Low Cardiac Output
01/01/1991 - "The efficacy of amrinone was assessed in the treatment of low cardiac output states occurring within 24 h after mitral valve replacement in an open prospective trial. "
01/01/1991 - "[Hemodynamic effects of amrinone in low cardiac output after mitral valve replacement]."
08/01/1990 - "Amrinone in perioperative low cardiac output syndrome."
12/01/1989 - "Amrinone: contemporary management of the low cardiac output syndrome. "
07/01/1988 - "[Clinical and hemodynamic multicenter study of the effect of intravenous amrinone in the treatment of low cardiac output after valvular replacement]."
|4.||Coronary Artery Disease (Coronary Atherosclerosis)
05/01/1994 - "We have studied the effects of amrinone on left and right ventricular haemodynamics in patients with impaired ventricular performance caused by coronary artery disease. "
12/01/1986 - "Peripheral hemodynamics and metabolic parameters were studied in 12 healthy volunteers (mean = 24.6 years) and in 12 patients with coronary artery disease (mean = 51.1 years) at rest and after isometric handgrip exercise both before and after application of amrinone (1.5 mg/kg body weight i.v.). "
07/01/1980 - "Accordingly, the hemodynamic, myocardial metabolic and ECG responses to amrinone (2.5 mg/kg i.v. over 1 hour) were measured in nine patients with congestive heart failure secondary to coronary artery disease. "
07/01/1980 - "Effects of amrinone on myocardial energy metabolism and hemodynamics in patients with severe congestive heart failure due to coronary artery disease."
07/01/1980 - "The amrinone-induced hemodynamic improvement in patients with congestive heart failure secondary to coronary artery disease was associated with reductions in MVO2 and CBF and no evidence of myocardial ischemia."
|5.||Myocardial Ischemia (Ischemic Heart Diseases)
02/01/1987 - "The effect of the positive inotropic agent amrinone on anatomic infarct size induced by coronary artery occlusion and reperfusion in dogs is unknown, although previous studies have shown that amrinone increases indices of myocardial ischemia during very brief coronary artery occlusions. "
12/01/1993 - "The effects of amrinone (CAS 60719-84-8) (10(-6) mol/l or 5 x 10(-5) mol/l) or milrinone (CAS 78415-72-2) 10(-5) mol/l) on myocardial ischemia extent and infarct size were compared in isolated electrically paced rabbit hearts (Langendorff, constant pressure: 70 cm H2O, Tyrode solution, Ca2+ 1.8 mmol/l). "
12/01/1993 - "Effect of amrinone and milrinone on myocardial ischemia extent and infarct size in isolated rabbit hearts."
10/01/1992 - "The incidence of myocardial ischemia as detected by Holter monitor was 36% with amrinone and 33% with dobutamine. "
12/01/1984 - "Clinically, amrinone therapy was complicated by sustained symptomatic ventricular tachycardia in four patients, worsening myocardial ischemia in four patients, and worsening congestive heart failure in eight patients, all of whom had been stable before entry into the study; only three of the 31 patients improved clinically. "
|3.||Type 3 Cyclic Nucleotide Phosphodiesterases
|5.||Vasodilator Agents (Vasodilators)
|1.||Cardiopulmonary Bypass (Heart-Lung Bypass)
|3.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)